GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PepGen Inc (NAS:PEPG) » Definitions » EV-to-EBIT

PepGen (PepGen) EV-to-EBIT : -3.54 (As of May. 25, 2024)


View and export this data going back to 2022. Start your Free Trial

What is PepGen EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, PepGen's Enterprise Value is $306.17 Mil. PepGen's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-86.53 Mil. Therefore, PepGen's EV-to-EBIT for today is -3.54.

The historical rank and industry rank for PepGen's EV-to-EBIT or its related term are showing as below:

PEPG' s EV-to-EBIT Range Over the Past 10 Years
Min: -15.32   Med: 0   Max: 42.22
Current: -3.54

During the past 4 years, the highest EV-to-EBIT of PepGen was 42.22. The lowest was -15.32. And the median was 0.00.

PEPG's EV-to-EBIT is ranked worse than
100% of 421 companies
in the Biotechnology industry
Industry Median: 10.43 vs PEPG: -3.54

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. PepGen's Enterprise Value for the quarter that ended in Mar. 2024 was $320.67 Mil. PepGen's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-86.53 Mil. PepGen's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -26.99%.


PepGen EV-to-EBIT Historical Data

The historical data trend for PepGen's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PepGen EV-to-EBIT Chart

PepGen Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
- - -2.34 -0.85

PepGen Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.03 -1.15 -0.13 -0.85 -3.71

Competitive Comparison of PepGen's EV-to-EBIT

For the Biotechnology subindustry, PepGen's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PepGen's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PepGen's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where PepGen's EV-to-EBIT falls into.



PepGen EV-to-EBIT Calculation

PepGen's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=306.167/-86.533
=-3.54

PepGen's current Enterprise Value is $306.17 Mil.
PepGen's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-86.53 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PepGen  (NAS:PEPG) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

PepGen's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=-86.533/320.67018
=-26.99 %

PepGen's Enterprise Value for the quarter that ended in Mar. 2024 was $320.67 Mil.
PepGen's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-86.53 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PepGen EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of PepGen's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


PepGen (PepGen) Business Description

Traded in Other Exchanges
N/A
Address
321 Harrison Avenue, 8th Floor, Boston, MA, USA, 02118
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
Executives
James G Mcarthur director, officer: President and CEO NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Jaya Goyal officer: See Remarks PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Habib J Dable director C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
James E Flynn 10 percent owner, other: *Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Laurie Keating director 300 THIRD STREET, CAMBRIDGE MA 02142
Christopher Ashton director PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Deerfield Management Company, L.p. (series C) 10 percent owner, other: *Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Michelle L Mellion officer: See Remarks PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Noel Donnelly officer: Chief Financial Officer PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Niels Svenstrup officer: See Remarks PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Sonia Bracegirdle officer: See Remarks PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Deerfield Mgmt V, L.p. 10 percent owner, other: *Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Deerfield Private Design Fund V, L.p. 10 percent owner, other: *Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Oxford Science Enterprises Plc 10 percent owner 46 WOODSTOCK ROAD, OXFORD X0 OX2 6HT